Telix Joins Thera4Care Theranostics Consortium
The Australian radiopharmaceutical company will contribute to a 27-partner European initiative testing terbium-161 cancer therapies.
Updated on Nov. 6, 2026 in Cancer
Telix has joined Thera4Care, a European theranostics consortium of 27 partners, and the group selected its FAP-targeting dimer DOTAGA.Glu.(FAPi)2 for phase 1 clinical testing with terbium-161. The project is co-funded under the Horizon Europe framework and includes partners from 14 European countries and the United States.
Why it matters
The collaboration aims to build an integrated, collaborative ecosystem for theranostics in Europe, pooling preclinical and clinical activity across multiple centres. Terbium-161 emits beta particles and Auger electrons over extremely short distances, a property the trial will test for safety and preliminary activity.
The consortium includes 27 partners spanning 14 European countries plus the United States, and the phase 1 trial targets FAP-expressing metastatic solid tumors. Clinical outcomes from the trial remain unknown, as the study is designed first to assess safety and preliminary activity.
The players
Telix Pharmaceuticals
Telix Pharmaceuticals is an Australian radiopharmaceutical company developing diagnostic and therapeutic imaging agents for cancer.
Thera4Care
Thera4Care is a European theranostics consortium of 27 partners, co-funded under the Horizon Europe framework, aiming to build an integrated ecosystem for the field.
The details
Telix will contribute to preclinical and clinical activities under the agreement, while the consortium will also evaluate scandium-44, copper-64 and copper-67 labelled compounds in preclinical work. The initial phase 1 trial will focus on ovarian and pancreatic cancers and sarcomas.
Timeline
November 6, 2026: Telix announced it had joined Thera4Care.
Health Landscape
Thera4Care is a multi-partner program funded under Horizon Europe, organized to pool preclinical and clinical theranostics work across institutions in 14 European countries and the United States. The collaboration reflects a shift from isolated company trials toward shared European infrastructure for radiopharmaceutical cancer therapy.
The trial is at an early stage and is not yet available as a treatment option for patients. Its initial focus on ovarian and pancreatic cancers and sarcomas means any future access would begin with those specific tumor types.
The takeaway
Patients with ovarian, pancreatic, or sarcoma diagnoses should discuss with their oncologists whether clinical trials for emerging radiopharmaceutical therapies are appropriate. Trial participation depends on eligibility criteria set by each study.
Further reading
Explore more in our Cancer section for broader context on treatment research.
Source note: This article includes information reported by Pharmabiz.
